Publications by authors named "M Pani"
Multiple sclerosis (MS) is a chronic, inflammatory, demyelinating, neurodegenerative disease of the central nervous system, significantly impacting patients' quality of life. Understanding patient and healthcare professional (HCP) preferences for MS treatments is crucial for optimizing therapeutic strategies and improving adherence and outcomes. This Discrete-Choice Experiment (DCE) assesses preferences for various MS treatment attributes among Italian patients and HCPs.
View Article and Find Full Text PDFArticle Synopsis
- Researchers studied the La-poor section of the La-Ni-Si ternary system, leading to the discovery of four new polar intermetallic compounds.
- The compounds exhibit various structures, including diamond-like frameworks and homoatomic/homopolyhedral arrangements, emphasizing the unique characteristics of each type.
- The study concludes that the similar sizes and electronegativities of nickel (Ni) and silicon (Si) atoms contribute to the rich diversity of compositions and structures found in these materials.
The role of the hospital pharmacist to guarantee access and continuity of care for the management of epilepsy.
Glob Reg Health Technol Assess
July 2024
In this article the pivotal role of hospital pharmacists in the multidisciplinary management of epilepsy is discussed. Hospital pharmacists are members of national and local ethics committees, oversee clinical trials, and ensure adherence to regulations for patient access to novel therapeutic treatments. They actively contribute to regulatory processes and the definition of prescribing centers.
View Article and Find Full Text PDFHospital pharmacists and their role in the management of epilepsy.
Glob Reg Health Technol Assess
July 2024
Background: Compassionate drug use (CDU) provides early access to not yet authorised medicines and is funded by pharmaceutical companies. The observational retrospective study Compass-O monitored the CDU of onco-haematological drugs, managed by seven Italian units for cytotoxic drug preparations (Unità Farmaci Antiblastici [UFA]), between 1 January, 2016 and 31 December, 2021.
Objective: We aimed to evaluate the CDU of onco-haematological drugs managed by seven Italian UFA, between 2016 and 2021.